TP53 and carcinoma: For instance, one study which included a large number of ECSs with low-grade carcinoma cases showed a lower range of TP53 mutations (62%) [57], whereas another study that investigated a low number of ECSs with low-grade carcinoma cases reported a high rate of TP53 mutations (91%) [10].